A study evaluating lipoprotein profile resulting from NGM282and effect of rosuvastatin on these changes in biopsy confirmed non alcoholic steatohepatitis patients.

Trial Profile

A study evaluating lipoprotein profile resulting from NGM282and effect of rosuvastatin on these changes in biopsy confirmed non alcoholic steatohepatitis patients.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs NGM 282 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 16 Nov 2017 New trial record
    • 24 Oct 2017 Results (n=21 from 1 mg cohort) presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top